Max Gelman
LightNews LightNews
banner
maxgelman.bsky.social
Max Gelman
@maxgelman.bsky.social
2K followers 110 following 65 posts
Reporting on pharma and biotech for Endpoints News. Baseball fan, Northwestern alum. Message me on Signal: maxgelman.37
Posts Replies Media Videos
maxgelman.bsky.social
Had a lot of great conversations reporting on this the last few months -- Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?

endpoints.news/are-pd-1xveg...
Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?
Summit Therapeutics is running late-stage trials for biopharma’s buzziest drug in lung cancer, but some industry experts believe ivonescimab and other PD-1xVEGF bispecifics may better target another t...
endpoints.news
October 16, 2025 at 3:53 PM
maxgelman.bsky.social
Had a lot of fun digging into the science about how this new startup wants to treat food allergies

endpoints.news/excellergy-d...
A fresh biotech has a radical plan to treat inflammation and allergies, setting its sights on Xolair
Startup Excellergy debuts with $70M Series A to develop drugs targeting allergic diseases, aiming to compete with Roche/Novartis' Xolair through new immune response approach.
endpoints.news
October 13, 2025 at 12:22 PM
maxgelman.bsky.social
Subcutaneous Keytruda approved in solid tumors endpoints.news/merck-wins-a...
Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug
FDA approves Keytruda Qlex, Merck's new subcutaneous formulation of Keytruda, offering more convenient administration and patent protection through 2039.
endpoints.news
September 19, 2025 at 6:26 PM
maxgelman.bsky.social
The Fed cut interest rates by a quarter point. How much will it move the needle for biotech?

endpoints.news/federal-rese...
The Fed cut interest rates by a quarter point. How much will it move the needle for biotech?
Biotechs and their investors have long called for lower interest rates since the pandemic’s free-flowing fundraising environment dried up a few years ago. But there are other challenges facing the industry.
endpoints.news
September 17, 2025 at 7:47 PM
maxgelman.bsky.social
Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s

endpoints.news/pfizer-has-a...
Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s
As Wall Street continues to digest this week’s disappointing results for Summit Therapeutics’ PD-1xVEGF bispecific cancer drug, Pfizer is primed to take advantage.
endpoints.news
September 12, 2025 at 4:28 PM
maxgelman.bsky.social
Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts

endpoints.news/summit-plays...
Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts
Summit Therapeutics is facing fresh scrutiny after mixed Phase 3 trial results for its cancer drug ivonescimab, leading to a 25% stock drop and questions about FDA approval.
endpoints.news
September 9, 2025 at 2:18 PM
maxgelman.bsky.social
A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try

endpoints.news/mitochondria...
A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try
NRG Therapeutics announced the close of a £50 million Series B round that should take it through a Phase 2 study in ALS and a Phase 1b trial in Parkinson’s.
endpoints.news
September 8, 2025 at 1:04 PM
maxgelman.bsky.social
Summit says long-awaited data in Western patients are a success. But they come with caveats

endpoints.news/wclc25-summi...
Summit says long-awaited data in Western patients are a success. But they come with caveats
Summit Therapeutics released a much-anticipated cut of ivonescimab data in North American and European lung cancer patients on Sunday,
endpoints.news
September 8, 2025 at 12:43 PM
maxgelman.bsky.social
SubQ Leqembi approved endpoints.news/fda-approves...
FDA approves Eisai and Biogen's subcutaneous Leqembi, gaining new ground in competition against Lilly
The FDA approved a new formulation of Eisai and Biogen’s Alzheimer’s drug Leqembi, an incremental step in the companies’ strategy to compete with Eli Lilly’s Kisunla.
endpoints.news
August 29, 2025 at 9:02 PM
maxgelman.bsky.social
A recent FDA approval was seen as a bellwether for Alnylam. Now its sales are through the roof.

endpoints.news/alnylam-shar...
Amvuttra's first full-quarter sales for ATTR-CM are in. And they're a boon for Alnylam
A recent label expansion is sending sales of Alnylam’s Amvuttra through the roof. The drug pulled in $492.0 million in revenue in the second quarter, up 114% from the ...
endpoints.news
July 31, 2025 at 12:26 PM
maxgelman.bsky.social
Breaking from @drewsnews.bsky.social: Vinay Prasad is out at FDA

endpoints.news/vinay-prasad...
Vinay Prasad is out at FDA, following Sarepta decision and vaccine controversies
FDA's CBER head Vinay Prasad exits agency after Sarepta gene therapy controversy and criticism over Covid vaccine decisions. Conservative media targeted his political views.
endpoints.news
July 30, 2025 at 12:59 AM
maxgelman.bsky.social
A small biotech's breast cancer drug more than tripled patient outcomes in a Phase 3 trial, putting it in position to displace medicines from Novartis and Roche.

endpoints.news/celcuity-pos...
Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche
Celcuity reports gedatolisib with fulvestrant reduced disease progression risk by 67% vs fulvestrant alone in Phase 3 breast cancer trial
endpoints.news
July 28, 2025 at 1:08 PM
maxgelman.bsky.social
FDA is holding an Expert Panel on the use of SSRIs during pregnancy this morning, but participants have long questioned antidepressant use endpoints.news/the-fdas-new...
The FDA’s new SSRI experts have long questioned antidepressant use
FDA panel on antidepressant use in pregnancy features experts known for opposing medical consensus, includes discussion with Commissioner Marty Makary on Monday.
endpoints.news
July 21, 2025 at 11:39 AM
maxgelman.bsky.social
Sat down virtually with Arvinas CEO John Houston about his announced retirement this morning, where we talked about PROTACs, the company's sliding stock price and what might happen with their Pfizer partnership

endpoints.news/retiring-arv...
Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer
John Houston is planning to retire at Arvinas after more than eight years at the helm, the company announced Wednesday, as its lead protein degrader program approaches an inflection point.
endpoints.news
July 9, 2025 at 6:05 PM
maxgelman.bsky.social
🍨🍨🍨 from Andy
June 24, 2025 at 5:48 PM
maxgelman.bsky.social
Another cancer drug approval coming weeks ahead of the deadline www.fda.gov/drugs/resour...
FDA grants accelerated approval to datopotamab deruxtecan-dlnk
On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.).
www.fda.gov
June 23, 2025 at 6:01 PM
maxgelman.bsky.social
One of my favorite Endpoints traditions is our annual look at the LGBTQ+ leaders in biopharma. We've got 13 awesome profiles this year, be sure to give it a read. And props to @kylelahucik.bsky.social for organizing it once again!

endpoints.news/biopharma-le...
Biopharma leaders carving a path for the industry’s LGBTQ+ community
Welcome to the fourth edition of Endpoints News’ special report on scientists, executives, investors and other stakeholders in the biopharma’s LGBTQ+ community.
endpoints.news
June 6, 2025 at 12:49 PM
maxgelman.bsky.social
Saturday AM #ASCO25 news!

Trodelvy+Keytruda "practice-changing" data: endpts.com/asco25-gilea...

Pfizer PROTAC no better than oral SERDs: endpts.com/asco25-arvin...

Enhertu extends life by 3 months in stomach cancer: endpts.com/asco25-enher...

Early data from Immatics: endpts.com/asco25-immat...
Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer
CHICAGO — Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of breast cancer. The combination of Trodelvy and Keytruda ...
endpts.com
May 31, 2025 at 12:54 PM
maxgelman.bsky.social
Summit blew up my morning 🫠🫠🫠 endpts.com/summits-disa...
Summit’s disappointing survival readout raises stakes for full data
Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data?
endpts.com
May 30, 2025 at 3:51 PM
Reposted by Max Gelman
nytimes.com
Robert F. Kennedy Jr., the health secretary, posted photos on Sunday of himself and his grandchildren swimming in a contaminated Washington creek where swimming is not allowed because it is used for sewer runoff.
RFK Jr. Swims in Washington Creek That Flows With Sewage and Bacteria
www.nytimes.com
May 13, 2025 at 1:00 AM
Reposted by Max Gelman
dansinker.com
Best Chicago controversy of the new Pope is the Cubs trying to lay claim to him and his brother having to speak up to clear up that he's a Sox fan. blockclubchicago.org/2025/05/08/p...
Pope Leo XIV Is A Sox Fan, Despite The Early Hope From Cubs Fans, His Brother Confirms
The Cubs' Marquee Sports Network, citing ABC News, said the new pontiff supports the North Siders. But his brother said that is not true.
blockclubchicago.org
May 8, 2025 at 9:16 PM
maxgelman.bsky.social
I spoke to some folks yesterday about Vinay Prasad’s appointment as director of CBER and what it means for biopharma.

endpts.com/vinay-prasad...
Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment
How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a hematologist-oncologist by training who gained prominence for criticizing ...
endpts.com
May 7, 2025 at 12:38 PM
maxgelman.bsky.social
Bristol Myers Squibb’s schizophrenia drug Cobenfy failed a Phase 3 study in the adjunctive setting, the company announced Tuesday afternoon.

endpts.com/bristol-myer...
Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment
Bristol Myers Squibb’s attempt to turn Cobenfy into a megablockbuster neuroscience drug ran into a stumbling block Tuesday afternoon.
endpts.com
April 22, 2025 at 9:23 PM
Reposted by Max Gelman
erictopol.bsky.social
Most people haven’t heard of this test, which is available in the US. It accurately predicts Alzheimer’s (not just if there’s a risk, but when). It is modulated by exercise and likely other lifestyle factors.
Here’s (almost) everything we know about it
erictopol.substack.com/p/the-breakt...
April 14, 2025 at 1:48 PM
maxgelman.bsky.social
Johnson & Johnson CEO Joaquin Duato subtly but assertively criticized President Donald Trump's plans for pharmaceutical tariffs, saying tax policy is a better way to onshore US drug manufacturing.

endpts.com/jj-ceo-chide...
J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing
The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.
endpts.com
April 15, 2025 at 7:46 PM